GMAB genmab.com: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Genmab A/S is a leading biotechnologist defending its position in the competitive oncology niche with unique patents. The EV/EBITDA dynamics of the business clearly illustrate market cycles, with the value holding at 26.32. Growth is accelerating through strategic alliances with pharma behemoths for joint trials. Financial stability relies on steady royalty payments, which mitigates the risks associated with new clinical developments.

GMAB (Genmab AS) riwayat Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan saka 23.11.2025 nganti 10.11.2026

Rincian metrik komprehensif lan analitis genmab.com (GMAB)

- rega saham lan target rega konsensus:

Kutipan saham Genmab US|GMAB - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Genmab Corp|GMAB - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Akuntansi saben Saham Genmab|GMAB - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku genmab.com|GMAB - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- indikator pendapatan resik lan kelipatan nilai:

GMAB - Penghasilan resik perusahaan|Proyeksi bathi mangsa ngarep Genmab A/S|GMAB - Pangali rega marang bathi|Prakiraan rega marang bathi Genmab A/S|GMAB - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Genmab Corp|GMAB - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Genmab|GMAB - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan genmab.com|GMAB - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Genmab A/S

Analisis dhasar perusahaan:Genmab US GMAB

High capital intensity is characteristic of the biotech sector and the EV/EBITDA valuation history of Genmab A/S (GMAB). This indicator compares the total enterprise value, including debt, with operating profit before depreciation and amortization. The calculation allows for an assessment of the asset payback period, stripped of the influence of the financing structure. Stable royalties from Darzalex and the DuoBody platform make this multiple key to analyzing the efficiency of R&D expenditures.

Analisis pesaing